United Therapeutics (NASDAQ:UTHR) EVP Sells $4,870,025.00 in Stock

Key Points

• EVP Paul Mahon sold $4,870,025 worth of United Therapeutics stock (8,300 shares at $586.75), trimming his stake by 15.52% to 45,172 shares valued at about $26.5 million.
• The company missed Q1 estimates (EPS $5.82 vs. ~$7.00 expected; revenue $781.5M vs. $797.4M), which coincided with a roughly 4.6% intraday share decline on elevated volume.
• Despite the earnings miss and recent insider sales, analysts are largely positive—MarketBeat shows a "Moderate Buy" consensus with an average price target near $619.42.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $586.75, for a total transaction of $4,870,025.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company's stock, valued at $26,504,671. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Down 4.6%

NASDAQ UTHR traded down $27.58 during trading on Thursday, reaching $569.18. The company's stock had a trading volume of 830,871 shares, compared to its average volume of 485,002. The stock has a market capitalization of $24.05 billion, a PE ratio of 20.40, a PEG ratio of 1.63 and a beta of 0.60. The business has a 50-day moving average price of $548.25 and a 200-day moving average price of $500.41. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the firm earned $6.63 earnings per share. United Therapeutics's revenue was down 1.6% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on UTHR shares. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating for the company in a research note on Thursday. Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research report on Thursday, March 12th. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Finally, TD Cowen boosted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a research report on Monday, March 30th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $619.42.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on Tyvaso IPF data and the blockbuster potential of ralinepag, which helped shares rally after the Q1 report despite the miss; this pipeline optimism can support longer‑term valuation. Zacks: UTHR Q1 Earnings Miss, Shares Jump on Strong Outlook
• Positive Sentiment: Company highlighted continued clinical progress (including positive ADVANCE O results noted in the press release), which supports revenue growth potential beyond near‑term quarterly fluctuations. BusinessWire: Q1 2026 Financial Results
• Positive Sentiment: Expansion of a DPI/inhaled delivery partnership ecosystem tied to United Therapeutics activity has supportive implications for commercial reach and Tyvaso delivery options. Market reaction to related partnership news lifted peers and signals strategic optionality. Investing.com: MannKind Stock Surges on United Therapeutics Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly (from $707 to $701) but kept an "outperform" rating — a modest technical downgrade that still implies meaningful upside versus current levels. Benzinga: RBC Lowers Price Target
• Neutral Sentiment: Several analysts have raised targets in recent months (UBS, BofA, Cantor, Oppenheimer), leaving a mixed analyst landscape—some higher targets offset by occasional trims. Investors are parsing these conflicting signals. MarketBeat: UTHR Analyst Coverage
• Negative Sentiment: Q1 results missed estimates: EPS $5.82 vs. consensus near $7.00 and revenue of $781.5M below expectations — a clear near‑term earnings and top‑line disappointment that pressures the stock. Zacks: UTHR Misses Q1 Estimates
• Negative Sentiment: Significant insider sales: CEO and CFO sold multi‑million dollar stakes earlier in the week, which markets often view as a negative signal about near‑term insider conviction. SEC Filing: Insider Sales

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Torren Management LLC bought a new stake in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the 4th quarter valued at $31,000. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.